Gastroesophageal reflux disease in primary care: Using changes in proton pump inhibitor therapy as an indicator of partial response

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 7, 2012, Pages 751-761

  Ruigómez, Ana ^a   Johansson, Saga ^b   Wernersson, Börje ^b   Fernández Cantero, Oscar ^a   García Rodríguez, Luis A ^a  

^a Department of Pharmacoepidemiology   (Spain)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

epidemiology; gastroesophageal reflux disease; proton pump inhibitor; residual symptoms

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INSULIN; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PROTON PUMP INHIBITOR; STEROID; WARFARIN;

ADULT; AGED; ANXIETY; ARTICLE; BARRETT ESOPHAGUS; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG RESPONSE; DRUG SUBSTITUTION; ESOPHAGUS ULCER; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANXIETY; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; DEPRESSION; DRUG PRESCRIPTIONS; ELECTRONIC HEALTH RECORDS; ESOPHAGITIS, PEPTIC; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PRIMARY HEALTH CARE; PROTON PUMP INHIBITORS; SEX FACTORS; TREATMENT OUTCOME; ULCER; YOUNG ADULT;

EID: 84862184690     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.679682     Document Type: Article

References (36)

1. Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, et al. American gastroenterological association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1383-91.
2. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux diseaselike symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004;4:CD002095.
3. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005;2:CD003245.
4. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010;32:720-37.
5. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 2005;22:79-94. (Pubitemid 41039696)
6. Vakil N, Veldhuyzen van Zanten S, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease (GERD) - a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20.
7. Diculescu M, Iacob R, Chira C, Mihaila D, Iacob S. Esomeprazole in the treatment of patients with heartburn and other upper gastrointestinal symptoms, referred to primary care -results of the in-practice evaluation program in Romania. Rom J Gastroenterol 2005;14:9-14. (Pubitemid 40460421)
8. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009;58:295-309.
9. Boeckxstaens GE, Denison H, Jensen JM, Lehmann A, Ruth M. Translational gastrointestinal pharmacology in the 21st century: 'the lesogaberan story'. Curr Opin Pharmacol 2011;11:630-3.
10. Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastroesophageal reflux disease. Aliment Pharmacol Ther 2010;32:334-43.
11. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401. (Pubitemid 46656860)
12. Stuart-Buttle CD, Read JD, Sanderson HF, Sutton YM. A language of health in action: Read Codes, classifications and groupings. A conference of the American Medical Informatics Association. AMIA Annual Fall Symposium 1996;75-9.
13. MULTILEX for primary care. 2010. Available from http://www.firstdatabank. co.uk/uploads/files/MultilexDDF%20for%20Primary%20Care.pdf.Accessed 25 January 2010.
14. García Rodríguez LA, Ruigómez A, Martín-Merino E, Johansson S, Wallander M-A. Relationship between gastroesophageal reflux disease and COPD in UK primary care. Chest 2008;134:1223-30.
15. Ruigómez A, García Rodríguez LA, Wallander MA, Johansson S, Dent J. Comparison of gastroesophageal reflux disease and heartburn diagnoses in UK primary care. Curr Med Res Opin 2006;22:1661-8. (Pubitemid 44449221)
16. Ruigómez A, García Rodríguez LA, Wallander MA, Johansson S, Graffner H, Dent J. Natural history of gastro- oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther 2004;20:751-60. (Pubitemid 39319230)
17. Ruigómez A, García Rodríguez LA, Wallander MA, Johansson S, Thomas M, Price D. Gastroesophageal reflux disease and asthma: a longitudinal study in UK general practice. Chest 2005;128:85-93. (Pubitemid 40994458)
18. Ruigómez A, Hungin AP, Lundborg P, Johansson S, Wallander MA, García Rodríguez LA. Treatment patterns in paediatric patients with a new diagnosis of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 2011;23:232-7.
19. Ruigómez A, Lundborg P, Johansson S, Wallander MA, García Rodríguez LA. Follow-up of a cohort of children and adolescents with gastro-esophageal reflux disease who were free of reflux esophagitis at initial diagnosis. Scand J Gastroenterol 2010;45:814-21.
20. Ruigómez A, Wallander M-A, Lundborg P, Johansson S, García Rodríguez LA. Gastroesophageal reflux disease in children and adolescents in primary care. Scand J Gastroenterol 2010;45:139-46.
21. El-Serag H, Hill C, Jones R. Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care - a review of studies using the UK General Practice Research Database. Aliment Pharmacol Ther 2009;29:470-80.
22. Gerson LB, Bonafede M, Princic N, Gregory C, Farr A, Balu S. Development of a refractory gastro-oesophageal reflux score using an administrative claims database. Aliment Pharmacol Ther 2011;34:555-67.
23. Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000;14:1589-94. (Pubitemid 32011732)
24. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? an evidence-based approach. Arch Intern Med 2006;166:965-71.
25. El-Serag H. Role of obesity in GORD-related disorders. Gut 2008;57:281-4. (Pubitemid 351288088)
26. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005;143:199-211. (Pubitemid 41076753)
27. Zerbib F, Belhocine K, Simon M, Capdepont M, Mion F, Bruley des Varannes S, et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut 2011;61:501-6.
28. Jansson C, Nordenstedt H, Wallander MA, Johansson S, Johnsen R, Hveem K, et al. Severe gastro-oesophageal reflux symptoms in relation to anxiety, depression and coping in a population-based study. Aliment Pharmacol Ther 2007;26:683-91. (Pubitemid 47246200)
29. Martin-Merino E, Ruigomez A, Garcia Rodriguez LA, Wallander MA, Johansson S. Depression and treatment with antidepressants are associated with the development of gastroesophageal reflux disease. Aliment Pharmacol Ther 2010;31:1132-40.
30. Martín-Merino E, Ruigómez A, Johansson S, Wallander M-A, García-Rodríguez LA. Study of a cohort of patients newly diagnosed with depression in general practice: prevalence, incidence, comorbidity and treatment patterns. Prim Care Companion J Clin Psychiatry 2010;12:e1-8.
31. Wiklund I, Carlsson R, Carlsson J, Glise H. Psychological factors as a predictor of treatment response in patients with heartburn: A pooled analysis of clinical trials. Scand J Gastroenterol 2006;41:288-93.
32. Heading RC, Monnikes H, Tholen A, Schmitt H. Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. BMC Gastroenterol 2011;11:52.
33. Vakil N, Niklasson A, Denison H, Ryden A. Partial responders to a proton pump inhibitor in gastroesophageal reflux disease: symptom profile and prevalence of irritable bowel syndrome, anxiety and depression. Gut 2011;60(Suppl 3): A266-abstract P0781.
34. Becher A, El-Serag H. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastrooesophageal reflux disease. Aliment Pharmacol Ther 2011;34:618-27.
35. Hungin AP, Hill C, Molloy-Bland M, Raghunath A. Systematic review: patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012;10:109-16.
36. Bytzer P, Mattsson H, Wernersson B. Partial symptom response to proton pump inhibitors in patients with nonerosive reflux disease and reflux esophagitis. Gastroenterology 2011;140(5 Suppl 1):S-583.